Ferric Derisomaltose
Brand names: Monoferric · Active ingredient: Ferric Derisomaltose
In short: Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-hemodialysis-dependent chronic kidney disease (NDD-CKD)
What is Ferric Derisomaltose used for?
Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:
who have intolerance to oral iron or have had unsatisfactory response to oral iron,
or
who have non-hemodialysis-dependent chronic kidney disease (NDD-CKD)
Ferric Derisomaltose dosage
For patients weighing 50 kg or more: Administer 1,000 mg of Monoferric by intravenous infusion over at least 20 minutes as a single dose. Repeat dose if iron deficiency anemia reoccurs.
For patients weighing less than 50 kg: Administer Monoferric as 20 mg/kg actual body weight by intravenous infusion over at least 20 minutes as a single dose. Repeat dose if iron deficiency anemia reoccurs.
The dosage of Monoferric is expressed in mg of elemental iron. Each mL of Monoferric contains 100 mg of elemental iron.
Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions .
Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives.
Each vial of Monoferric is single-dose only. Discard unused portion.
Withdraw the appropriate volume of Monoferric and dilute in 100 mL to 500 mL of 0.9% Sodium Chloride Injection, USP.
Final diluted concentration should be more than 1 mg iron/mL.
Compatibility of Monoferric with other drugs has not been established. Monoferric should not be mixed with or physically added to solutions containing other drugs.
Administer the prepared solution via intravenous infusion over at least 20 minutes.
Following dilution with 0.9% Sodium Chloride Injection, USP, Monoferric solution may be stored at room temperature [20° C to 25°C (68°F to 77°F)] for up to 12 hours.
Extravasation of Monoferric may cause brown discoloration at the extravasation site which may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Monoferric administration at that site.
Monitor patients for hypersensitivity reactions for 30 minutes after infusion completes.
The Monoferric solution for administration at the final diluted concentration of > 1 mg iron/mL is compatible with:
Infusion bags of various volumes up to 500 mL of 0.9% sodium chloride injection, USP
100 mL of Baxter® Mini-Bag PlusTM (and equivalent formats) containing 0.9% sodium chloride injection, USP
Transfer with Vial2Bag Advanced Admixture Devices to infusion bags of various volumes up to 500 mL of 0.9% sodium chloride injection, USP
How to take Ferric Derisomaltose — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Prior History of Allergies to Parenteral Iron Products
Question patients regarding any prior history of reactions to parenteral iron products .
Hypersensitivity Reactions
Advise patients to report any signs and symptoms of hypersensitivity that may develop during and following Monoferric administration, such as rash, itching, dizziness, lightheadedness, swelling and breathing problems .
Distributed by: Pharmacosmos Therapeutics Inc., Morristown, NJ 07960
Monoferric is manufactured under license from Pharmacosmos A/S, Denmark
Warnings & precautions
Do not take this medicine if: Monoferric is contraindicated in patients with a history of serious hypersensitivity to Monoferric or any of its components . Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Monoferric. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Monoferric is contraindicated in patients with prior serious hypersensitivity reactions to Monoferric or any of its components . In clinical trials in patients with IDA and CKD, serious or severe hypersensitivity were reported in 0.3% (6/2008) of the Monoferric treated subjects. These included 3 events of hypersensitivity in 3 patients; 2 events of infusion-related reactions in 2 patients and 1 event of asthma in one patient.
Excessive therapy with parenteral iron can lead to excess iron storage and possibly iatrogenic hemosiderosis or hemochromatosis. Monitor the hematologic response (hemoglobin and hematocrit) and iron parameters (serum ferritin and transferrin saturation) during parenteral iron therapy. Do not administer Monoferric to patients with iron overload .
Ferric Derisomaltose side effects
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
Hypersensitivity Reactions .
Iron Overload .
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.
The safety of Monoferric was evaluated in 3008 patients with iron deficiency anemia enrolled in two randomized, actively-controlled trials. Trial 1 enrolled adult patients with iron deficiency anemia with intolerance to oral iron or had an unsatisfactory response to oral iron with a clinical need for repletion of iron stores. Eligible subjects were required to have a baseline hemoglobin of ≤11g/dl, transferrin saturation (TSAT) of less than 20% and serum ferritin level of <100 ng/mL. Trial 2 enrolled adult patients with non-dialysis dependent chronic kidney disease (CKD) with iron deficiency anemia . Eligible subjects also had to have serum ferritin ≤100 ng/mL or ≤300 ng/mL if TSAT ≤30%.
Trial 1 and Trial 2
In the two randomized, actively-controlled clinical trials, Trial 1 and Trial 2 , patients were randomized in a 2:1 ratio to intravenous Monoferric (n = 2008) or intravenous iron sucrose (n = 1000) respectively. …
About this medicine
Monoferric is an iron replacement product containing ferric derisomaltose for intravenous infusion. Ferric derisomaltose is an iron carbohydrate complex with a matrix structure composed of interchanging layers of ferric hydroxide and the carbohydrate derisomaltose. Derisomaltose consists of linear, hydrogenated isomaltooligosaccharides with an average molecular weight of 1000 Da and a narrow molecular weight distribution that is almost devoid of mono- and disaccharides.
Ferric derisomaltose has an average molecular weight of 155,000 Da and has the following empirical formula:
{FeO(1-3X) (OH)(1+3X) (C6H5O7
3-)X}, (H20)T, -
(C6H10O6)R(-C6H10O5-)Z(C6H13O5)R, (NaCl)Y
X = 0.0311; T = 0.25; R = 0.14; Z = 0.49; Y = 0.14
Iron atoms placed in the electronegative cavities of the 3-D structure between and within the derisomaltose molecules. A schematic representation is presented below
Monoferric is a sterile, dark brown, non-transparent aqueous solution with pH 5.0-7.0, containing ferric derisomaltose dissolved in water for injections and filled into Type I glass vials. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 55859d2d-0456-4fa9-b41f-f535accc97db. Read the full official label on DailyMed.